Literature DB >> 6239685

Deficient expression of class-I HLA in some cases of acute leukemia.

W L Elkins, A Pickard, G R Pierson.   

Abstract

Leukemic cells from the blood and marrow of 25 cases of newly diagnosed acute leukemia were presented as target cells to alloreactive effector cells from unrelated normal donors in cell-mediated cytotoxicity assays. In three cases the leukemic targets were poorly killed relative to nonleukemic, HLA-identical target cells. The poor killing of the leukemic cells from one of these cases was shown by competitive inhibition to be due to deficient expression of normal class-I HLA antigens rather than resistance to lysis. Furthermore, the leukemic cells from these three patients were also deficient in binding monoclonal antibodies to nonpolymorphic determinants of class-I HLA and B2 microglobulin. Two additional cases were identified as having a less extensive deficit of HLA, and may be representative of a group with relatively subtle changes in these cell surface antigens. The possible significance of reduced expression of HLA in leukemic progression and in susceptibility to graft-vs-leukemia reactions after bone marrow transplantation is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239685     DOI: 10.1007/bf00205741

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells.

Authors:  J M Zarling; H I Robins; P C Raich; F H Bach; M L Bach
Journal:  Nature       Date:  1978-07-20       Impact factor: 49.962

2.  A rodent class I MHC determinant is shared among many species.

Authors:  H C Boyd; T A Potter; T V Rajan; C M Zmijewski; T J McKearn
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

3.  Resistance to cell-mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukemia.

Authors:  W Schmidt; H Festenstein
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

4.  Cytotoxic T lymphocyte lines (CTLL) against a human minor alloantigen.

Authors:  K S Zier; W L Elkins; G R Pierson
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

5.  Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV40 virus. Immunoresistance in vivo correlates with phenotypic loss of H-2Kk.

Authors:  L R Gooding
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

6.  Cell lines producing human T-cell lymphoma virus show altered HLA expression.

Authors:  D L Mann; M Popovic; P Sarin; C Murray; M S Reitz; D M Strong; B F Haynes; R C Gallo; W A Blattner
Journal:  Nature       Date:  1983 Sep 1-7       Impact factor: 49.962

7.  Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.

Authors:  S K Lee; R T Oliver
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

8.  Recognitive specificity of human cytotoxic T lymphocytes. I. Antigen-specific inhibition of human cell-mediated lympholysis.

Authors:  P M Sondel; F H Bach
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

9.  Monoclonal rat anti-major histocompatibility complex antibodies display specificity for rat, mouse, and human target cells.

Authors:  D E Smilek; H C Boyd; D B Wilson; C M Zmijewski; F W Fitch; T J McKearn
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus.

Authors:  H Mitsuya; L A Matis; M Megson; P A Bunn; C Murray; D L Mann; R C Gallo; S Broder
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  5 in total

1.  Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.

Authors:  G Venton; Y Labiad; J Colle; A Fino; S Afridi; M Torres; S Monteuil; B Loriod; N Fernandez-Nunez; L Farnault; P Suchon; J C Mattei; P Rihet; A Bergon; C Nguyen; C Baier; R Costello
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

2.  Analysis of HLA class Ia transcripts in human leukaemias.

Authors:  Durjoy Majumder; Debasis Bandyopadhyay; Sarmila Chandra; Ashis Mukhopadhayay; Nandini Mukherjee; Subir K Bandyopadhyay; Subrata Banerjee
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

3.  Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Authors:  Benjamin Joachim Schmiedel; Antje Werner; Julia Steinbacher; Tina Nuebling; Corina Buechele; Ludger Grosse-Hovest; Helmut Rainer Salih
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

4.  Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome.

Authors:  L J Medeiros; A B Gelb; K Wolfson; R Doggett; B McGregor; R S Cox; S J Horning; R A Warnke
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

5.  Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells.

Authors:  K Tanaka; H Hayashi; C Hamada; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.